U.S. pharma huge copyright scrapped two experimental weight loss capsules past year—a the moment-day-to-day tablet, lotiglipron, resulting from elevated liver enzymes and also a 2 times-everyday capsule, danuglipron, resulting from strong Unintended effects—but CEO Albert Bourla has explained the company is decided to “Perform and acquire”